These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25140894)

  • 1. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
    Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
    Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical assessment of tumor regression grade systems in gastroesophageal adenocarcinoma following neoadjuvant chemotherapy.
    Lütken C; Sheikh K; Willemoe GL; Achiam MP; Hasselby JP
    Pathol Res Pract; 2021 Aug; 224():153538. PubMed ID: 34243107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
    Fleischmann A; Thalmann GN; Perren A; Seiler R
    Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
    Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
    Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.
    Becker K; Langer R; Reim D; Novotny A; Meyer zum Buschenfelde C; Engel J; Friess H; Hofler H
    Ann Surg; 2011 May; 253(5):934-9. PubMed ID: 21490451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
    Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
    Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy.
    Langer R; Becker K; Zlobec I; Gertler R; Sisic L; Büchler M; Lordick F; Slotta-Huspenina J; Weichert W; Höfler H; Feith M; Ott K
    Ann Surg Oncol; 2014 Mar; 21(3):915-21. PubMed ID: 24281419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas.
    Langer R; Ott K; Feith M; Lordick F; Siewert JR; Becker K
    Mod Pathol; 2009 Dec; 22(12):1555-63. PubMed ID: 19801967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.
    Thies S; Guldener L; Slotta-Huspenina J; Zlobec I; Koelzer VH; Lugli A; Kröll D; Seiler CA; Feith M; Langer R
    Hum Pathol; 2016 Jun; 52():1-8. PubMed ID: 26980046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
    Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems.
    Chetty R; Gill P; Govender D; Bateman A; Chang HJ; Deshpande V; Driman D; Gomez M; Greywoode G; Jaynes E; Lee CS; Locketz M; Rowsell C; Rullier A; Serra S; Shepherd N; Szentgyorgyi E; Vajpeyi R; Wang LM; Bateman A
    Hum Pathol; 2012 Nov; 43(11):1917-23. PubMed ID: 22575264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.
    Langer R; Becker K
    Virchows Arch; 2018 Feb; 472(2):175-186. PubMed ID: 28918544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes.
    Tsekrekos A; Vieth M; Ndegwa N; Bateman A; Flejou JF; Grabsch HI; Mastracci L; Meijer SL; Saragoni L; Sheahan K; Shetye J; Yantiss R; Lundell L; Detlefsen S
    Hum Pathol; 2021 Oct; 116():94-101. PubMed ID: 34284051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey.
    Saliba G; Detlefsen S; Carneiro F; Conner J; Dorer R; Fléjou JF; Hahn H; Kamaradova K; Mastracci L; Meijer SL; Sabo E; Sheahan K; Riddell R; Wang N; Yantiss RK; Lundell L; Low D; Vieth M; Klevebro F
    Hum Pathol; 2021 Feb; 108():60-67. PubMed ID: 33221343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.